Phase 4 N=87 Adalimumab in JIA-associated Uveitis Stopping Trial
Uveitis · JIA
Primary: Time to Treatment Failure — NA; 119 Time to treatment failure (days) — p=<0.0001
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=6 Human Anti-Tac (Daclizumab) to Treat Juvenile Idiopathic Arthritis (JIA)-Associated Uveitis
Anterior Uveitis · Arthritis, Juvenile Idiopathic · Iritis
Primary: Number of Participants With a Two-step Reduction in Inflammation — 5 participants
N/A N=10 Golimumab in Juvenile Idiopathic Arthritis-associated Uveitis Failing Adalimumab
JIA Associated Uveitis
Primary: Number of Participants Reported as Complete Responders to Golimumab — 8 Participants
Phase 3 N=783 Preventing Extension of Oligoarticular Juvenile Idiopathic Arthritis JIA (Limit-JIA)
Juvenile Idiopathic Arthritis
Primary: Composite of All Primary Endpoints — 13; 14; 41; 245 Participants — p=0.7357
Phase 3 N=32 Active Juvenile Idiopathic Arthritis (JIA) Compassionate Use
Juvenile Idiopathic Arthritis
Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) — 29; 5 participants
Phase 3 N=133 Study of Human Anti-TNF Monoclonal Antibody Adalimumab in Children With Polyarticular Juvenile Idiopathic Arthritis (JIA)
Arthritis, Juvenile Idiopathic
Primary: Number of Subjects in the Non-MTX Stratum With Disease Flare During the Double-Blind Phase — 13; 20 Participants — p=0.031
Phase 2 N=8 Ustekinumab (STELARA) for the Treatment of Active Sight-Threatening Uveitis (STAR Study)
Uveitis
Primary: Number of Participants Experiencing a Treatment Response by Week 16 — 4; 2 Participants
Phase 3 N=225 Efficacy Study Of Tofacitinib In Pediatric JIA Population
Juvenile Idiopathic Arthritis
Primary: Double Blind Phase: Percentage of Participants With Disease Flare According to Pediatric Rheumatology Collaborative Study Group/Pediatric Rheumatology International…
Phase 4 N=85 Trial of Early Aggressive Drug Therapy in Juvenile Idiopathic Arthritis
Juvenile Chronic Polyarthritis · Juvenile Idiopathic Arthritis · Juvenile Rheumatoid Arthritis
Primary: Proportion of Participants Who Attain Inactive Disease by 6 Months — 10; 17 participants
N/A N=113 Enbrel-Juvenile Idiopathic Arthritis (JIA) Use Results Survey [All-Case Surveillance]
Juvenile Idiopathic Arthritis
Primary: Number of Participants With Treatment-Related Adverse Events of Etanercept — 22 participants
Phase 4 N=13 Multi Center Prospective Registry of Infliximab Use for Childhood Uveitis
Chronic Uveitis
Primary: Effects of Infliximab on Uveitis Disease Activity. — 3; 6 participants
Phase 3 N=227 Adalimumab vs. Conventional Immunosuppression for Uveitis Trial
Uveitis
Primary: Corticosteroid-sparing Treatment Success Within the First 6 Months After Randomization — 0.69; 0.54 Cumulative proportion of participants — p=0.029
Phase 3 N=302 Long-Term Safety Study Of Tofacitinib In Patients With Juvenile Idiopathic Arthritis
Juvenile Idiopathic Arthritis
Primary: Number of Participants With Laboratory Test Abnormalities — 294 Participants
Phase 3 N=239 Efficacy and Safety of Adalimumab in Patients With Active Uveitis
Uveitis
Primary: Time to Treatment Failure on or After Week 6 — 3.0; 5.6; 3.0; 4.8 months — p=<0.001
Phase 3 N=193 Pediatric Arthritis Study of Certolizumab Pegol
Polyarticular-course Juvenile Idiopathic Arthritis (JIA)
Primary: Certolizumab Pegol (CZP) Plasma Concentration Level at Week 16 — 1.6166; 9.2277; 13.8928; 22.9060 ug/ml
Phase 3 N=261 Efficacy and Safety of Adalimumab in Subjects With Inactive Uveitis
Uveitis
Primary: Time to Treatment Failure on or After Week 2 — 8.3; NA; 5.6; NA months — p=0.004
Phase 3 N=127 Extension Study Evaluating Etanercept in 3 Subtypes of Childhood Arthritis
Juvenile Idiopahtic Arthritis
Primary: Number of Participants With Malignancy: All Periods of Parent and Extension Study — 1 Participants
Phase 4 N=12 Open-label Safety and Pharmacokinetic Study of DUEXIS® (Ibuprofen and Famotidine) Tablets in Juvenile Idiopathic Arthritis
Juvenile Idiopathic Arthritis
Primary: Number of Participants Reporting Treatment Emergent Adverse Events (TEAEs) — 12; 7; 5; 0 participants
Phase 4 N=101 The Incidence of Extra-Articular Manifestations in Participants With Ankylosing Spondylitis Treated With Golimumab (MK-8259-012)
Ankylosing Spondylitis
Primary: Occurence Rate of Uveitis Attacks in Participants Before Anti-TNF/GLM Treatment and After the Start of GLM Treatment — 0.08; 0.08 Ratio — p=1.0000
Phase 2 N=10 Abatacept in the Treatment of Uveitis
Uveitis
Primary: Adverse Events — 0; 0; 0 Participants
Phase 3 N=86 Secukinumab Safety and Efficacy in Juvenile Psoriatic Arthritis (JPsA) and Enthesitis-related Arthritis (ERA)
Juvenile Psoriatic Arthritis · Enthesitis-related Arthritis
Primary: Number of Participants Experiencing a Flare During Treatment Period 2 — 10; 21 Participants — p=<0.001
Phase 2 N=16 Safety and Efficacy of AIN457 in Noninfectious Uveitis
Non-infectious Uveitis
Primary: Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs) and Who Died — 0; 0; 1; 1 participants
Phase 3 N=112 A Study of RoActemra/Actemra (Tocilizumab) in Patients With Active Systemic Juvenile Idiopathic Arthritis (JIA)
Juvenile Idiopathic Arthritis
Primary: Part I: Percentage of Participants With ≥30% Improvement in Juvenile Idiopathic Arthritis (JIA) American College of Rheumatology (ACR) Core Set and Absence of Fever…
Phase 3 N=55 An Extension Study of Subcutaneous Secukinumab in Patients With Juvenile Psoriatic Arthritis (JPsA) and Enthesitis Related Arthritis (ERA)
Juvenile Psoriatic Arthritis · Enthesitis Related Arthritis
Primary: Percentage of Participants With Juvenile Idiopathic Arthritis American College of Rheumatology (JIA ACR) 30 Response — 100; 100; 100; 100 Percentage of Participants
Phase 2 N=58 Phase II Study to Analyze Sarilumab in Non-Infectious Uveitis
Uveitis
Primary: Percentage of Participants With at Least 2-step Reduction in Vitreous Haze (VH) or Prednisone Dose <10 mg/Day at Week 16 — 30.0; 46.1 Percentage of participants — p=0.2354
Phase 3 N=188 A Study of Tocilizumab in Patients With Active Polyarticular Juvenile Idiopathic Arthritis
Juvenile Idiopathic Arthritis
Primary: Percent of Patients With a Juvenile Idiopathic Arthritis (JIA) American College of Rheumatology 30 (ACR30) Flare in Part II of the Study (Weeks 16-40) — 48.1; 25.6…
Phase 2 N=71 Safety and Effectiveness of Rilonacept for Treating Systemic Juvenile Idiopathic Arthritis in Children and Young Adults
Juvenile Idiopathic Arthritis
Primary: Time to Response to Treatment, as Determined by a Modified JIA ACR30 Requiring no Fever, Coupled With a Requirement for Corticosteroid Taper in Participants Who Are…
Phase 3 N=7 A Long-Term Extension Study of RoActemra/Actemra (Tocilizumab) in Patients With Juvenile Idiopathic Arthritis Who Completed WA19977 Core Study
Juvenile Idiopathic Arthritis
Primary: Number of Participants With Adverse Events of Special Interest and Study-Drug Related Adverse Events — 6; 0; 1; 1 participants
Phase 2 N=31 Adalimumab (Humira) in the Treatment of Refractory Non-infectious Uveitis
Uveitis
Primary: Cumulative Endpoint — 21 participants
Phase 3 N=190 BMS-188667 in Children and Adolescents With Juvenile Rheumatoid Arthritis
Juvenile Rheumatoid Arthritis
Primary: Time to Occurrence of Juvenile Rheumatoid Arthritis/Juvenile Idiopathic Arthritis (JRA/JIA) Disease Flare During Double-Blind Phase (Period B) — NA; 6 months — p=0.0002